TxCell SA, a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, and Lonza Pharma & Biotech, one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets, has announced entering into a Master Service Agreement for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation.